Article Information
History
- October 5, 2022.
Article Versions
- Version 1 (September 20, 2022 - 15:03).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Akshita Gupta1,2,*,
- Angelina Konnova1,2,*,
- Mathias Smet1,2,*,
- Matilda Berkell1,2,*,
- Alessia Savoldi3,
- Matteo Morra3,
- Vincent Van averbeke1,
- Fien De Winter1,
- Denise Peserico4,
- Elisa Danese4,
- An Hotterbeekx1,
- Elda Righi3,
- mAb ORCHESTRA working group,
- Pasquale De Nardo3,
- Evelina Tacconelli3,
- Surbhi Malhotra Kumar2,# and
- Samir Kumar Singh1,2,#,†
- 1Molecular Pathology Group, Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- 2Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
- 3Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
- 4Section of Clinical Biochemistry, University of Verona, Verona, Italy
- 5School of Health Sciences, University of Brighton, Brighton, United Kingdom
- 6Section of Microbiology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
- ↵†Correspondence: samir.kumarsingh{at}uantwerpen.be
Posted October 05, 2022.
Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
